Abstract: Methods and compounds are disclosed for irreversibly inhibiting a DNA repair enzyme that possesses lyase activity.

Abstract: Antimicrobial compounds and compositions of Formula (I) and methods of use are disclosed.

Abstract: Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX and Formula X that are highly active against the HCV virus when administered in an effective amount to a host in need thereof. The host can be a human or any animal that carries the viral infection. Methods of treating a subject suffering from a condition related to viral infections are also provided.

Abstract: A method for the purification of allopregnanolone is disclosed. Allopregnanolone prepared from isopregnanolone contains impurities such as triphenylphosphine oxide and other unknown impurities. To remove these impurities and purify allopregnanolone, the allopregananolone is dissolved in acetonitrile, and crystallized from the acetonitrile. The resulting crystallized allopregnanolone may then be re-crystallized from acetonitrile to further purify the allopregnanolone.

Abstract: A method for extracting phytosterols from tall oil pitch. The method involves saponifying tall oil pitch using an alkali in a polyatomic alcohol, extracting unsaponified matter from the alkali-alcohol solution using a hydrocarbon solvent, subsequently removing the solvent by distillation, and concentrating the phytosterols, wherein a mixture of paraffin hydrocarbons is used as said hydrocarbon solvent, and, following extraction from the extraction solution, betulin is isolated by crystallization and the phytosterols are then concentrated by means of rectification. This method enables an increase in the extraction rate of phytosterols from a saponified tall oil pitch up to 95%, producing the end product with phytosterol content of at least 65% with unwanted betulin impurities at no more than 0.3%.

Abstract: Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.

Abstract: The present invention provides a particular branched chain-containing aromatic compound. The branched chain-containing aromatic compound of the present invention is easily-soluble in isopropyl acetate superior in liquid-separation operability, and can be used for a production method of peptide and the like, which provides a final product simply by extraction separation, without crystallization and isolation of each intermediate in each step.

Abstract: Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance.

Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.

Abstract: Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, MALT lymphoma), benign neoplasm, a disease associated with angiogenesis, an autoimmune disease, an inflammatory disease, an autoinflammatory disease) by administering a compound of Formula (I).

Abstract: Provided are methods for identifying OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts and compounds of Formula 1 for eliciting antibodies that specifically and selectively bind to the OP adducts, wherein the Formula 1 compounds have the structure of OP-Peptide-Linker-CP, wherein CP is a carrier protein, OP represents a structure corresponding to that of a reactive organic phosphorous compound covalently modifying a tyrosine residue hydroxyl group of the peptide of Formula I and the other variable groups are as described herein.

Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.

Abstract: Melanocortin receptor-specific peptides with a C-terminal naphthylalanine of the formula: where R4, R7, R9, R11, R18, R20, R21a, R21b, R21c and R22 are as defined in the claims, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin receptor-mediated or responsive diseases, indications, conditions and syndromes.

Abstract: The present invention relates to novel low substituted polymyxins and compositions thereof.

Abstract: Cyclic peptide of formula I X1-GQRETPEGAEAKPWY-X2, wherein X1 comprises an amino acid (sequence), with 1 to 4 members, comprising natural and unnatural amino acids, and X2 comprises a natural amino acid, and wherein X1 comprises the N-terminal amino acid left in position 1, and X2 the C-terminal amino acid in the ultimate, right position, in the form of a lyophilisate without additives and/or stabilizers and its use.

Abstract: Stable pre-fusion class I fusion proteins in the pre-fusion conformation, including one or more mutations in the hinge-loop that is present between the base helix and the RR1, are described.

Abstract: The disclosure relates to compositions, pharmaceutical compositions, vaccines, and methods of making and using the same. The compositions of the disclosure are useful to stimulate an antigen-specific immune response and, in some embodiments, a protective immune response in an animal after challenge to pathogens. The compositions of the disclosure are also useful for treatment and prevention of disease in a subject such as cancer.

Abstract: The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels.

Abstract: The invention discloses the use of an artificial protein for isolating a nucleosome, the nucleosome comprising a multiple-modified histone protein octamer, wherein the artificial protein comprises a first histone modification binding domain of 50 to 200 amino acids binding to a first histone modification, a second histone modification binding domain of 50 to 200 amino acids binding to a second histone modification, a linker of 5 to 50 amino acids connecting the first and the second histone modification binding domain, and an affinity tag. Further disclosed are a nucleic acid encoding the artificial protein, a host cell comprising the nucleic acid and a kit for isolating a nucleosome, the nucleosome comprising a multiple-modified histone protein octamer. Further disclosed is an in-vitro method for isolating a nucleosome having a first and a second histone modification.

Abstract: A method for establishing eukaryotic expression cell line of CD36 mutant gene that encodes CD36 deficiency, the method including: (1) extracting total RNA from a whole blood sample derived from a CD36-deficient individual, and amplifying a coding sequence (CDS) in CD36 mRNA, to obtain a cDNA sequence fragment of the mutant CD36 gene; (2) splicing and amplifying the mutant CD36 gene and the EGFP fluorescent gene by SOE-PCR (Gene Splicing By Overlap Extension PCR) using four forward and reverse primers, to obtain a mutant gene fragment of MT-CD36-EGFP; (3) constructing and amplifying a MT-CD36-EGFP-pLV4/StripII-HIS10 eukaryotic expression vector including the mutant CD36 gene and the EGFP fluorescent gene; (4) transfecting the MT-CD36-EGFP-pLV4/StripII-HIS10 eukaryotic expression vector into the CHO-K1 cell line by using virus-mediated transfection of eukaryotic cells.

Abstract: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present disclosure relates to a method for producing a TLR5 agonist protein. According to the present disclosure, the TLR5 agonist protein can be easily separated and purified after biotechnological production. In particular, the fusion partner used for separation and purification is effectively removed so as to minimize the possibility of inhibiting binding to TLR5 and inducing an immune response by the fusion partner.

Abstract: The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties.

Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.

Abstract: The present invention discloses a method for treating wounds and for accelerating the healing of wounds by administering an effective amount of a pharmaceutical composition containing type VII collagen protein, mini-C7 protein, variants thereof or any combinations thereof. The pharmaceutical composition may be administered through a variety of routes including intravenous injection, topical application, or oral ingestion. The method may further include administering a genetically modified fibroblast capable of expressing type VII collagen protein, mini-C7 protein, variants thereof or small growth factors to achieve synergistic healing effect.

Abstract: It is described the preparation of Insulin like peptides, of chimeric Insulin like peptides and of their derivatives by the random combination of their chains A and their chains B and the pharmaceutical application of the obtained products.

Abstract: The present invention relates to a binding molecule comprising at least three binding specificities, wherein (a) the first specificity is for a Hepatitis B virus (HBV) surface antigen selected from HBV small surface antigen, HBV medium surface antigen and HBV large surface antigen; (b) (i) the second and third specificity are for CD3 and CD28, respectively; or (ii) the second and third specificity are selected from specificities for CD16, CD56, NKp30, NKp46, 4-1BB and NKG2D; and (c) each binding specificity is provided by one or more binding sites, each binding site being independently provided by (i) a set of six complementarity determining regions (CDRs), wherein said set of six CDRs consists of a first set of three CDRs and a second set of three CDRs, wherein said first and said second set is each comprised in an immunoglobulin domain; or (ii) a set of three CDRs, wherein said set of three CDRs is comprised in an immunoglobulin domain.

Abstract: The invention is a method for reducing the effector functions of a therapeutic neutralizing antibody by administering to the afflicted subject an effective amount of an engineered aglycosylated human monoclonal antibody containing an engineered Fc region, wherein aglycosylation of the Fc region prevents therapeutic antibody-mediated cell activation, inflammation, C1q binding to the antibody and antibody triggered classical pathway activation.

Abstract: Provided herein are methods shifting the isoelectric profile of a recombinant protein product and the use of such methods in the manufacture of recombinant protein products. Also provided are recombinant protein products produced by such methods.

Abstract: The invention provides anti-Tau antibodies and methods of using the same.

Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.

Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.

Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

Abstract: CAR cells targeting and antibodies human HLA-DR are described as a new method of cancer treatment. It is proposed that HLA-DR CAR cells are safe and effective in patients and can be used to treat human tumors expressing the HLA-DR.

Abstract: The present invention provides, among other things, methods and compositions for treating chronic lung disorders, in particular, bronchopulmonary dysplasia (BPD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to BPD an effective amount of an anti-Flt-1 antibody, or antigen binding fragment thereof, such that at least one symptom or feature of BPD is reduced in intensity, severity, or frequency, or has delayed onset.

Abstract: The present disclosure relates to anti-canine platelet derived growth factor receptor alpha antibodies binding to canine platelet derived growth factor receptor alpha.

Abstract: The present disclosure relates, in general, to methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Abstract: Anti-CD133 monoclonal antibodies having advantageous properties; products, compositions and kits comprising the monoclonal antibodies; methods (processes) of making the monoclonal antibodies and related compositions, as well as methods of using the monoclonal antibodies in analytical, diagnostic and therapeutic applications.

Abstract: The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds an Fc?R that activates a cellular effector (“Fc?RActivating,” such as Fc?RIIA or Fc?RIIIA) and an Fc?R that inhibits a cellular effector (“Fc?RInhibiting,” such as Fc?RIIA) with an altered Ratio of Affinities relative to the respective binding affinities of such Fc?R for the Fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by Fc?R is desired (e.g.

Abstract: A wet chemistry method for preparing spherical celluloid beads by mixing a water-based suspension solution and a solvent based celluloid solution that is immiscible in the suspension solution. The two combined solutions create an “oil-in-water” type mixture where the dispersed phase consists of celluloid dissolved in solvent and co-solvent that is suspended in the continuous water phase. Agitation and removal of the solvent and co-solvent mixture produces spherical shaped celluloid beads.

Abstract: A process for modifying a natural rubber is provided. The process comprises at least the following steps: i. providing at least one natural rubber and epoxidizing the natural rubber to obtain an epoxidized natural rubber, or providing a pre-epoxidized natural rubber, ii. grafting, to the epoxidized natural rubber or to the pre-epoxidized natural rubber, at least one 1,3-dipolar compound having at least one nitrogen atom. A modified natural rubber capable of being obtained by the process and also rubber compositions based on the modified natural rubber is also provided.

Abstract: Methods and systems for olefin polymerization are provided. The method for olefin polymerization can include flowing a catalyst through an injection nozzle and into a fluidized bed disposed within a reactor. The method can also include flowing a feed comprising one or more monomers, one or more inert fluids, or a combination thereof through the injection nozzle and into the fluidized bed. The feed can be at a temperature greater than ambient temperature. The method can also include contacting one or more olefins with the catalyst within the fluidized bed at conditions sufficient to produce a polyolefin.

Abstract: A method of making a branched polymer comprising (C?C)—(C?C)—CO groups is provided. The method comprises: (i) Providing, in admixture, at least one monofunctional monomer comprising one polymerisable carbon-carbon double bond per monomer, at least one multifunctional monomer comprising at least two polymerisable carbon-carbon double bonds per monomer, at least one chain transfer agent comprising a carbonyl group; (ii) Forming a polymer from the mixture; and (iii) Hydrolysing the polymer. A branched polymer is further provided.

Abstract: The present invention relates to a super absorbent polymer and a method for preparing the same. According to the super absorbent polymer and the method for preparing a super absorbent polymer of the present invention, a laponite is contained in a colloidal solution state during polymerization of the monomer composition, and thus achieves an appropriate crosslinking density, thereby contributing to improvement of various physical properties such as a gel strength and a centrifuge retention capacity of the super absorbent polymer.

Abstract: Provided is a method of preparing a rubber composition, which includes (a) reacting a conjugated diene-based monomer with one or more of compounds in the presence of a first catalyst; (b) adding a conjugated diene-based monomer to a product of the step (a) and inducing a reaction; and (c) adding a second catalyst and a conjugated diene-based monomer to a product of the step (b) and inducing a reaction.

Abstract: A mobile vacuum distillation unit for extracting, condensing, and collecting volatile organic compound vapor emissions from one or more polymer-containing articles includes a shell that defines an enclosed interior space and is mounted to a transportable support platform, a vacuum distillation vessel, a condenser, a condensate storage tank, and a vacuum pump system in fluid communication with a vacuum distillation chamber of the vacuum distillation vessel. The vacuum distillation chamber that includes the one or more polymer-containing articles from which the VOC vapor emissions are extracted may be heated by an exhaust gas heat exchanger if the transportable support platform is connected to and hauled by a tractor unit powered by a diesel engine. A method of using the mobile vacuum distillation unit to extract VOC vapor emissions from one or more polymer-containing article during transportation of the one or more polymer-containing articles between geographically separate destinations is also disclosed.

Abstract: Catalyst Systems, processes of forming the same and polymers and polymerization processes are described herein.